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Faecal neutrophil elastase-antiprotease balance
reflects colitis severity
Rachael Barry 1, David Ruano-Gallego1, Shiva T Radhakrishnan2,3, Scott Lovell4, Lu Yu5, Olga Kotik1, Izabela Glegola-Madejska1,
Edward W Tate4, Jyoti S Choudhary5, Horace R T Williams2,3 and Gad Frankel 1
Given the global burden of diarrheal diseases on healthcare it is surprising how little is known about the drivers of disease severity.
Colitis caused by infection and inflammatory bowel disease (IBD) is characterised by neutrophil infiltration into the intestinal
mucosa and yet our understanding of neutrophil responses during colitis is incomplete. Using infectious (Citrobacter rodentium) and
chemical (dextran sulphate sodium; DSS) murine colitis models, as well as human IBD samples, we find that faecal neutrophil
elastase (NE) activity reflects disease severity. During C. rodentium infection intestinal epithelial cells secrete the serine protease
inhibitor SerpinA3N to inhibit and mitigate tissue damage caused by extracellular NE. Mice suffering from severe infection produce
insufficient SerpinA3N to control excessive NE activity. This activity contributes to colitis severity as infection of these mice with a
recombinant C. rodentium strain producing and secreting SerpinA3N reduces tissue damage. Thus, uncontrolled luminal NE activity
is involved in severe colitis. Taken together, our findings suggest that NE activity could be a useful faecal biomarker for assessing
disease severity as well as therapeutic target for both infectious and chronic inflammatory colitis.
Mucosal Immunology (2020) 13:322–333; https://doi.org/10.1038/s41385-019-0235-4
INTRODUCTION
Inflammatory diarrhoeal diseases are major health concerns world-
wide. Inflammatory diarrhoea can result from infections with enteric
pathogens or chronic illnesses, such as inflammatory bowel diseases
(IBDs), including Crohn’s disease (CD) and ulcerative colitis (UC).1
Although the cause is different, disease pathology is similar,
including dysbiosis, disruption of the mucosal barrier and extensive
inflammation. Mild cases of colitis can be managed, but severe cases
result in lethality in the case of infection or continual relapse and
therapy resistance in IBD patients. Thus, understanding the drivers of
disease severity will uncover improved strategies for disease
management and alternative therapeutic approaches.
A widely used murine model of IBD is chemically induced colitis
using dextran sulphate sodium (DSS). DSS is delivered via drinking
water and induces tissue damage and inflammation, which most
closely resembles human UC. Although the mechanism by which
DSS triggers colitis is not well defined, the severity of disease can be
modified based on the concentration and duration of exposure.2
The natural mouse pathogen Citrobacter rodentium has been
extensively used to model disease caused by the human gastro-
intestinal pathogens enteropathogenic and enterohaemorrhagic
Escherichia coli (EPEC and EHEC) in a true physiological host.3–5 Due
to the similarities in disease, C. rodentium infection can also help
elucidate the mechanisms of IBD pathogenesis.6 Using a type III
secretion system, which injects a repertoire of effector proteins into
intestinal epithelial cells (IECs). Citrobacter rodentium intimately binds
to the colonic epithelium, where it causes intestinal inflammation
and tissue damage.3 Moreover, shortly after mucosal colonisation
C. rodentium triggers extensive reprogramming of cell proliferation
and metabolic processes in IECs.7–9 Importantly, the severity of colitis
differs depending on the mouse strain. While some strains (e.g.
C57BL/6) infected with C. rodentium present self-limiting mild colitis,
others (e.g. C3H derivates and FVB) present severe symptoms,
including signs of discomfort, diarrhoea and weight loss, which
is fatal.3,10 Differences in host genetics such as R-spondin 2
expression and the composition of the gut microbiota have been
previously identified as factors, which determine colitis severity
upon C. rodentium infection.11–13
In this study, we tested the hypothesis that uncontrolled
neutrophil responses contribute to colitis severity. Neutrophils kill
pathogenic microorganisms by phagocytosis, neutrophil extra-
cellular trap formation (NETosis) and/or by releasing the toxic
contents of their granules in the extracellular milieu (degranula-
tion). Neutrophils are required for the clearance of C. rodentium;
however, the mechanisms are largely unknown.14 Recently, it has
been shown that C. rodentium triggers NETosis in vitro and that
NET formation is required for clearance in vivo.15,16 Both NETosis
and degranulation results in the release of reactive oxygen and
nitrogen species (ROS and RNS), peroxidases including myeloper-
oxidase (MPO) and proteolytic enzymes such as neutrophil
elastase (NE), cathepsin G and proteinase 3, which are contained
within azurophilic granules.17,18 These potent agents are unable to
distinguish host cells from bacterial targets and if not tightly
controlled have damaging consequences on host tissue.
To control the unintentional damaging effects of extracellular
proteases, affected tissues secrete specific inhibitors that form
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stable complexes with proteases and block their activity. For
example, NE can be inhibited by Elafin (human-specific), secretory
leucocyte protease inhibitor (SLPI) and members of the serpin
superfamily, for example, SERPINA1.19,20 Serine protease inhibitors
(Serpins) are suicide substrates that contain a reactive centre loop
(RCL), which is directly targeted by their cognate protease.21
Cleavage of the inhibitor distorts the catalytic site of the protease,
leading to an irreversible interaction with the Serpin. In mice,
SerpinA3N has been reported to be the inhibitor of NE released
from T lymphocytes in an in vivo model of neuropathic pain.22
SerpinA3N is considered the murine orthologue of human α-1-
antichymotrypsin (SERPINA3); however, the RCL of SerpinA3N is
identical to α-1-antitrypsin (SERPINA1) and has been reported to
share functions of human SERPINA1 and SERPINA3, including the
ability to inhibit NE.23
Here we compared mild and severe models of infection- and
chemical-induced colitis and found that mice exhibiting severe
colitis have measurable levels of NE activity in faeces. Mechan-
istically, we show that this is due to an imbalance in NE and a
serine protease inhibitor, SerpinA3N, which is produced by IECs
during C. rodentium infection. By profiling IBD patient samples
with active and inactive disease, we reveal that NE activity also
reflects colitis severity in humans. Consistent with the notion that
NE activity contributes to colitis, disease severity was reduced by
infection with an engineered C. rodentium strain secreting
SerpinA3N. Together, our data illustrate that the balance between
antiproteases, such as SerpinA3N, and NE reflects colitis severity.
RESULTS
Mice suffering from severe C. rodentium-induced disease exhibit
extensive intestinal cell death
To further our understanding of the mechanisms driving colitis,
we have focused on the two mouse strains, C57BL/6 (C57) and
C3H/HeNCrl (C3H), which display different disease severities.4,10 As
previously reported, we observed that C. rodentium causes a self-
limiting infection in C57 mice, which display mild disease
pathology with little to no weight loss over the duration of
infection (Fig. 1a, b). In contrast, C3H mice succumb to infection as
bacterial colonisation peaks earlier and results in high levels of
weight loss and diarrhoea (Fig. 1a, b). Colonic crypt hyperplasia
(CCH), a key characteristic of C. rodentium infection was observed
in both mouse strains (Fig. S1)
To assess the extent of tissue damage, we performed
hematoxylin and eosin staining on colonic tissue sections
collected at the peak of infection, when C. rodentium numbers
had reached maximal levels of 1 × 109 CFU/g of faeces. This
corresponds to 6 days post inoculation (dpi) for C3H and 8 dpi for
C57 mice (Fig. 1a). This revealed that mice C3H mice have
extensive tissue damage and erosion of the epithelium compared
to infected C57 mice (Fig. 1c, arrows). To determine the extent of
damage at the cellular level, TUNEL staining was performed to
measure the number of apoptotic cells in an infected colon. As
expected, uninfected tissue from both mouse strains had very few
(<15 TUNEL-positive cells; Fig. 1d, e). Infected C57 mice had an
average of 59.4 TUNEL-positive cells per transverse colon section,
whereas infected C3H mice had an average of 480 TUNEL-positive
cells (Fig. 1e). Accordingly, the severe disease pathology observed
in the C3H mice following C. rodentium infection correlates with
extensive tissue damage and an increase in apoptotic cells.
Neutrophil infiltration into the intestinal mucosa is a character-
istic of colitis. For example, S100A8 and S100A9 (calprotectin)
constitute ~45% of the cytoplasmic content of neutrophils and is
used as a non-invasive faecal biomarker for assessing colonic
inflammation in IBD.24 We therefore tested if neutrophil numbers
vary following C. rodentium infection of C57 and C3H mice.
We measured calprotectin levels (S100A8) by enzyme-linked
immunosorbent assay (ELISA) in faecal samples collected from
uninfected and infected mice. While calprotectin increased upon
infection, no difference was observed between C57 and C3H mice
(Fig. 2a). To quantify the number of neutrophils specifically
recruited to the colonic mucosa of infected mice, we stained
transverse tissue sections with Ly6G, a marker expressed
predominantly on neutrophils. In agreement with calprotectin
levels, the number of neutrophils infiltrating the mucosa did not
differ between mouse strains (Fig. 2b and Fig. S2A). Tissue sections
were also stained with an antibody against NE, which is localised
within the azurophil granules of neutrophils. NE stained in a
granular pattern localised within Ly6G-positive cells, with no
apparent difference in intracellular NE staining between C57 and
C3H mice (Fig. S2A, B). Together, this indicates that the number of
neutrophils at the peak on infection does not differ in mice with
mild and severe disease.
Faecal NE activity is only detected in mice with severe disease
As NE has long been known to be the primary cause of tissue
damage in chronic inflammatory conditions of the lung,25 we
hypothesised that excessive NE release may be contributing to
disease severity in C. rodentium-infected C3H mice. To test this
hypothesis, we first used a commercially available fluorogenic
tetrapeptide substrate targeted by NE (Ala-Ala-Pro-Val) to measure
faecal NE activity (Fig. S3A). As a positive control, we included
recombinant mouse NE (rNE), which efficiently cleaved the substrate
(Fig. S3A and Fig. 2c). When the substrate was added to faecal
samples, NE activity was only detected in faeces from infected C3H
mice and not in samples from uninfected mice or infected C57 mice.
Since more specific and sensitive substrates for human NE
containing unnatural amino acids have been reported,26 we
generated one such substrate with a Arg(NO2) residue at position
P4 amino acid, (Arg(NO2)-Met(O2)-Oic-Abu; Fig. S3B). Arg(NO2) was
chosen because it is a bulky hydrophilic amino acid, which is
preferred for both human and mouse NE.26,27 Using rNE we
demonstrated that the optimised substrate was 58 times better
hydrolysed by rNE than the commercial substrate and was therefore
used for all subsequent NE activity assays (Fig. S3C). Repeating the
assay using the optimised substrate in the mouse faecal samples
revealed similar results to the commercial substrate, suggesting that
both substrates are indeed being cleaved by NE present in faecal
samples from mice with severe disease (Fig. 2c). Furthermore, the
addition of NE inhibitor Sivelestat significantly reduced faecal NE
activity in C3H mice (Fig. 2c, grey boxes). These data suggest that
active NE is present in faeces of mice suffering from severe C.
rodentium infection, which may be the underlying reason for tissue
damage at the inflamed site.
Faecal NE activity defines disease severity in chemically induced
colitis
To determine the role of NE activity in an alternative model of
colitis, we utilised the DSS colitis model. To model mild and severe
diseases, we used a low (1.5%) and high (3%) dose of DSS in C57
mice, respectively. The difference in disease severity was validated
by histological analysis, TUNEL staining, weight loss and short-
ening of colon length (Fig. S4A–C). Mice treated with 3% DSS
reached humane endpoint (20% weight loss) by day 8 whereas
mice treated with 1.5% DSS only lost ~5% body mass (Fig. S4C). In
addition, histology and TUNEL staining revealed more tissue
damage and enhanced cell death in mice with severe disease (3%
DSS). Disease activity index (DAI; combination weight loss,
diarrhoeal and haematochezia score) was higher in mice with
severe disease (3% DSS) compared to mild disease (1.5% DSS;
Fig. S4D). S100A8 and MPO ELISA was performed on faecal
samples collected prior to treatment and at day eight as surrogate
readouts for neutrophil recruitment and release of azurophil
granules, respectively. Although increased calprotectin and MPO
was observed in faeces from both groups, there was no difference
in levels between mice with mild and severe disease, suggesting
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similar neutrophil recruitment and degranulation at 8 days post
treatment (Fig. 2d and Fig. S4E). As we observed for infection-
induced colitis, faecal NE activity was only detected in mice with
severe colitis (Fig. 2e). Taken together, the correlation between
tissue damage and NE activity reflects disease severity in murine
models of chemically induced and infection-induced colitis.
NE activity reflects clinical activity in human IBD
To translate our findings to human disease, we measured faecal
NE activity in samples from patients with active and inactive UC
and compared it to their clinical DAI (Table 1). Based on previous
studies, a DAI of ≥5 was used as a sign of clinical relapse and
therefore active disease.28 Samples were also sent for calprotectin
measurements to enable a direct comparison with the current
most commonly used faecal marker. The NE activity test was
performed by measuring the rate of substrate cleavage for each
sample and the rate grouped based on clinical activity: a
significant difference was observed between patients classified
as having inactive or active disease (Fig. 3a). To calculate the
diagnostic ability of NE activity a receiver operator characteristic
(ROC) curve analysis was performed: the areas under curve (AUC)
obtained were 0.8681 and 0.8462 for faecal NE activity and
calprotectin measurements, respectively (Fig. 4b). While the
sample size is small (n= 27), these analyses have directly
compared NE activity with calprotectin levels in the same faecal
sample. Furthermore, the AUC obtained for calprotectin is similar
to the results of previous studies.29 This suggests that faecal NE
activity predicts clinical DAI with comparable accuracy to
calprotectin and therefore may offer an additional faecal marker
for identifying disease activity in UC patients.
Inflamed IECs secrete SerpinA3N
To protect against extracellular proteases activity inflamed mucosa
secrete inhibitors that form stable complexes with the proteases.
Fig. 1 Disease severity induced by intestinal infection differs depending on mouse strain. a Intestinal colonisation of C. rodentium as measured
by CFU/g of stool in C57 and C3H mice. Data are represented as mean ± SD, n= 10. b Weights presented as percentage of initial weight. C57
mice plotted in black circles and C3H in grey squares. Data are represented as mean ± SD, n= 10. c Histological analysis of colonic sections;
black arrows indicate erosion of epithelium observed only in C3H mice. Scale= 200 μM. d Representative images of TUNEL-stained colon
sections from infected mice quantified in e. Green: TUNEL; blue: DAPI. Scale= 200 μM. e Quantification of the number of TUNEL-positive cells
per transverse section of colons from individual mice. Multiple comparison one-way ANOVA, *** P ≤ 0.001.
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We therefore hypothesised that the observed faecal NE activity in
C57 and C3H mice reflects differential expression of cognate
Serpins by IECs, as a means for protection against NE-induced
damage. We took advantage of the global proteomic analysis we
had previously performed on IECs enriched from colons of infected
C57 mice.7,30 By comparing infected to uninfected IECs, an
increased abundance of >1.5-fold change (log 2 >0.58) was
observed for SerpinD1, SerpinA3M and SerpinA3N in four
biological repeats. (Fig. 4a). Importantly, SerpinA3M and SerpinA3N
are members of the same Serpin family (α-1-antichymotrypsin) and
Fig. 2 NE activity reflects severity of disease induced by C. rodentium and DSS. a Levels of S100A8 (calprotectin) in faeces from uninfected and
infected mice (8 dpi: C57-closed circles; 6 dpi: C3H-closed squares) as determined by ELISA. Multiple comparison one-way ANOVA, n.s.= non-
significant, *P ≤ 0.05, ***P ≤ 0.001. b The number of Ly6G-positive cells were counted per colonic section from individual mice (n= 8–9).
Multiple comparison one-way ANOVA, n.s.= non-significant, *P ≤ 0.05, **P ≤ 0.01. Representative images shown Fig. S2. c Measurements of
faecal NE activity in uninfected and infected (C57, 8 dpi-closed circles; C3H, 6 dpi-closed squares) mice, measured using a fluorogenic
tetrapeptide substrate. Purified recombinant NE was used as a control (diamond). Grey squares indicate samples treated with Sivelestat.
Multiple comparison one-way ANOVA, ***P ≤ 0.001. d Faecal S100A8 ELISA (calprotectin) of samples taken from C57 mice pre-treatment (0)
and at 8 days post treatment (1.5% DSS- closed circles; 3% DSS- closed squares). Multiple comparison one-way ANOVA, n.s.= non-significant,
**P ≤ 0.01. e Faecal NE activity in samples from C57 mice pre-treatment (0) and at 8 days post treatment (1.5% DSS- closed circles; 3% DSS-
closed squares). Purified rNE was used as a control (diamond). Grey squares indicate samples treated with Sivelestat. Multiple comparison one-
way ANOVA, *P ≤ 0.05.
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SerpinA3N is a previously reported inhibitor of NE in vivo.22
Western blot analysis of SerpinA3N in IECs from C57 and C3H mice
revealed an increased abundance in both strains upon infection
(Fig. 4b). Next, to determine whether Serpina3n is transcriptionally
induced in response to infection, we performed quantitative real-
time PCR (qRT-PCR). Serpina3n expression was increased at the
peak of infection by ~3-fold and 20-fold in C57 and C3H mice,
respectively (Fig. 4c). Of note, Serpina3m was undetectable in both
uninfected and infected IECs from both mouse strains. These
results indicate that SerpinA3N is transcriptionally induced and
expressed by IECs following C. rodentium infection. As SerpinA3N is
produced by IECs in both C57 and C3H mice, we hypothesised that
the level of SerpinA3N in C3H mice is insufficient to neutralise
luminal NE activity.
Proteolytic activity of NE is balanced by SerpinA3N in mild
disease
Although produced by IECs, SerpinA3N is secreted to function
extracellularly. Therefore, to analyse the presence of extracellular
SerpinA3N, we performed western blot analysis of faecal samples
collected from C57 and C3H mice at the peak of C. rodentium
colonisation. Immunoblotting of faecal samples from uninfected
mice, using a SerpinA3N antibody, identified a single faint band at
~40 kDa (Fig. 5a). In contrast, two main products were detected in
faecal samples from infected C57 mice (mild disease). The lower
band corresponds to free SerpinA3N, while the band at 65 kDa is
SerpinA3N in a complex with a protease, since the irreversible
protease–serpin interaction is not disrupted by denaturation.
The difference in molecular weight between the free SerpinA3N
and the protease–SerpinA3N complex of ~25 kDa corresponds
to the molecular weight of NE. We also probed for another
reported murine NE inhibitor, SLPI. Although detected in infected
IECs, no SLPI was present in faeces, suggesting that it is not
secreted or unstable and that SerpinA3N is the main inhibitor of
NE in an inflamed colon (Fig. S5). Importantly, while the
SerpinA3N–protease complex was detected in faecal samples
from infected C3H mice, the free SerpinA3N was undetectable
(Fig. 5a). Based on these observations, we hypothesised that
the balance between SerpinA3N and NE in mild disease (C57) is in
favour of the inhibitor (i.e. excess free SerpinA3N), whereas in mice
with severe disease (C3H), the balance is in favour of NE (i.e.
insufficient SerpinA3N to neutralise luminal NE).
To test the hypothesis that mice with mild disease have surplus
SerpinA3N, we incubated active recombinant NE with faecal
samples from infected C57 mice. As positive control, we demon-
strated that recombinant (r) SerpinA3N efficiently inhibited rNE
activity (Fig. 5b and Fig. S3D, E). Furthermore, western blot analysis
of rSerpinA3N incubated with rNE revealed a SerpinA3N-NE
complex at 75 kDa using both SerpinA3N and NE antibodies
(Fig. 5d). Of note, rSerpinA3N runs at a higher molecular weight
than faecal SerpinA3N, likely due to cleavage of SerpinA3N by
unknown protease/s present in feaces. Next, we added increasing
amounts of C57 faecal sample (excess SerpinA3N) to activated rNE;
1mg/ml of faeces significantly inhibited rNE activity (Fig. 5b). As a
control, incubation of rNE with faecal samples from infected C3H,
which have active NE, did not alter NE activity (Fig. 5c). Together,
this supports the notion that faecal samples from infected C57 mice
have SerpinA3N in excess, whereas C3H mice have excessive NE.
Neutrophils in mice with severe colitis degranulate earlier than
mice with mild disease
To investigate why NE-SerpinA3N is imbalanced in C3H mice,
faecal samples were collected at timepoints leading up to the peak
of infection. Calprotectin levels are significantly increased at 4 dpi
in both C57 and C3H mice (Fig. S6).8 This suggests similar temporal
neutrophil recruitment irrespective of mouse strain. We therefore
hypothesised that the differences between the two mouse strains
is due degranulation. To test this, we quantified MPO levels in
faeces by ELISA. Released MPO levels were significantly higher
3 days earlier in C3H mice compared to C57 (day 4 vs. day 7;
Fig. 6a, b). As MPO is present in azurophilic granules, like NE, this
suggests that NE is also released at this early timepoint in C3H
mice. We therefore measured faecal NE activity and performed
western analysis of SerpinA3N over time. In C3H mice, faecal NE
activity was detected from 3 dpi, which corresponds to smearing
pattern of SerpinA3N by western blot (Fig. 6d, f). From 4 dpi all
SerpinA3N is in a higher molecular weight complex, correlating
with high NE activity. In contrast, no faecal NE activity was detected
in infected C57 mice and free SerpinA3N was present at all
timepoints (Fig. 6c, e). Together, these results suggest that
Fig. 3 Faecal NE activity predicts clinical activity in UC patients. a Mann–Whitney test of rate of cleavage of NE substrate in IBD samples from
ulcerative colitis (UC) patients classified as having inactive (circles, n= 13) and active (squares, n= 14) disease, ***P ≤ 0.001. b Receiver
operating characteristic (ROC) curve analysis of accuracy of NE activity and faecal calprotectin to predict active and inactive disease. Area
under curve (AUC) for NE activity= 0.8681 and 0.8462 for calprotectin.
Table 1. Clinical characteristics of human UC patients
Distribution N (%)
Proctitis 6 (22%)
Left sided UC 9 (33%)
Pancolitis 12 (45%)
Gender N (%)
Male 11 (41%)
Female 16 (59%)
Mean age of patients 39.9 (range 18–72)
Activity (SCCAI)
<5 (inactive) 13
≥5 (active) 14
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neutrophils in C3H mice undergo degranulation much earlier than
C57 mice, leading to an accumulation of NE activity which
saturates all available SerpinA3N.
Citrobacter rodentium producing SerpinA3N protects mice from
tissue damage
To test whether we could tilt the balance in favour of SerpinA3N in
C3H mice, we engineered a C. rodentium strain that produces and
secretes mouse SerpinA3N into the extracellular milieu. We fused a
His-tagged SerpinA3N lacking the eukaryotic signal peptide to the
bacterial HlyA secretion signal for expression in C. rodentium. The
type I/HlyA secretion system allows the secretion of proteins
directly from the bacterial cytoplasm.31 The supernatant obtained
after growing this strain was affinity purified and SerpinA3N-HlyA
was detected by western blotting (Fig. 7a). To measure the
inhibitory capacity of secreted His-SerpinA3N-HlyA, rNE was
incubated with the purified protein and NE activity measured.
SerpinA3N-HylA inhibited rNE as efficiently as recombinantly
expressed His-SerpinA3N (Fig. 7b and Fig. S3D, E). Once the
inhibitory activity of the SerpinA3N-HlyA was confirmed, we
engineered a C. rodentium strain (named ICC2031) that constric-
tively expresses the SerpinA3N-HlyA operon from the chromosome.
Fig. 4 SerpinA3N is produced by infected IECs. a Log 2 fold change of Serpins identified in proteomic analysis of IECs from uninfected and
infected C57 (8 dpi) mice. Black dots indicate proteins with increased or decreased abundance above or below 1.5-fold change, log 2: 0.585
(red line) in four individual experiments: SerpinA3M, SerpinA3N, SerpinB6, SerpinD1. b Western blot analysis using anti-SerpinA3N antibody
on enriched IECs samples from three uninfected and three infected C57 and C3H mice. Anti-Hsp90 was used as a loading control. Bar graph
below blot is quantification of SerpinA3N band relative to loading control; the actual values are indicated in italics above each bar. c mRNA
levels of Serpina3n expressed by infected and uninfected IECs measured by qRT-PCR relative to Gapdh control. Values are expressed as ΔΔCT
relative to uninfected, Mann–Whitney test, *P ≤ 0.05.
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ICC2031 had no growth defect when grown in vitro in minimal
medium; moreover, ICC2031 colonisation in vivo and CCH was
comparable to the parental wild-type (WT) strain (Fig. S7A, B and
Fig. 7c). Furthermore, neutrophil recruitment and release of
azurophil granules was similar between mice infected with the
WT and ICC2031 strains at peak of infection (Fig. 7d–f). However, NE
activity at the peak of infection was significantly reduced in C3H
mice infected with the ICC2031 compared to WT C. rodentium,
indicating that the reduction in NE activity is specifically due to the
secretion of SerpinA3N (Fig. 7g).
Based on our working hypothesis that excessive NE activity is
contributing to disease severity in C3H mice, the reduction in NE
activity after infection with ICC2031 should result in decreased
tissue damage. To determine the extent of damage, we collected
Fig. 5 SerpinA3N is secreted during infection and inhibits NE activity. a Western blot analysis of faecal samples taken from three uninfected
and three infected C57 (8 dpi) and C3H (6 dpi) mice using anti-SerpinA3N antibody. Free SerpinA3N (ca. 40 kDa) is detected in uninfected mice
and infected C57. In both C57 and C3H mice, a band at ~55 kDa (arrow) corresponds to a protease–SerpinA3N complex. Bar graph below blot
is quantification band/s intensity; actual values are indicated in italics above each bar. b Faecal samples from infected C57 mice (1 mg/ml-
triangles) significantly inhibit recombinant NE (rNE) activity whereas BSA (circles) or lower concentrations (0.1mg/ml-inverted triangles;
0.01mg/ml-diamonds) did not. Recombinant SerpinA3N inhibits rNE (squares). Grey circles are NE activity in faecal samples from C57 mice
without rNE. Multiple comparison one-way ANOVA, n.s.= non-significant, ***P ≤ 0.001. c Rate of NE substrate cleavage by rNE pre-incubated
with faecal samples from C3H (squares) or BSA (circles). Multiple comparison one-way ANOVA, n.s.= non-significant, **P ≤ 0.01, ***P ≤ 0.001.
d Western blot analysis of recombinant (r) SerpinA3N incubated with or without activated rNE. Band at ca. 75 kDa is complexed SerpinA3N
and NE, which is present in both SerpinA3N and NE blots.
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colons from infected C3H mice at 6 dpi and performed TUNEL
staining. Compared to WT infection, mice infected with ICC2031
have significantly reduced TUNEL-positive cells (Fig. 7h). Of note,
the extent of tissue damage correlated with the amount of NE
activity in the corresponding faecal sample because outlier
samples based on the NE activity assay also had the opposite
results in the TUNEL analysis (Fig. 7g, h, highlighted points). To
determine the contribution of NE to disease severity, we infected
mice with WT and ICC2013 and continued the experiment until
mice reached humane endpoint (20% weight loss). Only 14% of
mice infected with WT C. rodentium survived infection, whereas
53% of infected with ICC2031 survived (Fig. 7i). In addition, mice
infected with ICC2031 had a reduced diarrhoeal score at 11 dpi
(Fig. 7j). We also observed a similar trend treating mice
intrarectally with Sivelestat (Fig. S8A–D). These results corroborate
the notion that in a hyper-inflamed colon, high NE levels
overwhelms the available SerpinA3N resulting in tissue damage,
which contributes to disease severity (Fig. 8).
DISCUSSION
Citrobacter rodentium has been widely used to model human
enteric pathogens in the context of a physiological host. However,
the inflammatory signatures of C. rodentium infection closely
resemble those seen in IBD, including neutrophil infiltration,
mucosal damage and the involvement of key cytokines and innate
immune receptors, such as NOD2.3,32 Therefore, C. rodentium
infection is emerging as a model of IBD. Here, we show that NE is
released and drives mucosal tissue damage during infectious
colitis. By extrapolating from our findings using C. rodentium, we
reveal that faecal activity of NE also reflects disease severity in the
DSS colitis model as well as in human IBD. Our proof-of-concept
Fig. 6 Neutrophils in C3H mice degranulate earlier than C57 mice. Levels of MPO in faeces from infected C57 (a) or C3H (b) mice over time as
determined by ELISA. Multiple comparison one-way ANOVA, **P ≤ 0.01, ***P ≤ 0.001. c Analysis of faecal NE activity in infected C57 mice
collected overtime. Multiple comparison one-way ANOVA was performed, no significant difference. d Analysis of faecal NE activity in infected
C3H mice collected overtime. Multiple comparison one-way ANOVA was performed, *P ≤ 0.05, **P ≤ 0.01. e Western blot analysis using anti-
SerpinA3N antibody of faecal samples taken from infected C57 (e) or C3H (f) mice over time. Lower band (ca. 40 kDa) is free SerpinA3N and
upper band (>50 kDa) is SerpinA3N in complex with protease. Bar graphs below each blot is quantification band/s intensity; the actual values
are indicated in italics above each bar.
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study using faeces from patients with UC suggests that faecal NE
activity is equivalent to the current gold-standard maker
calprotectin for predicting active disease in UC patients. However,
in the murine models of infection-induced and chemically induced
colitis, NE activity successfully distinguished between disease
severity, whereas calprotectin did not. Calprotectin is released
from neutrophils early during inflammation and does not directly
contribute to tissue damage.33 In contrast, NE is released as a last
line of defence usually from damaged or dying neutrophils and
active NE directly contributes to tissue damage at inflamed sites.34
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Therefore, faecal NE activity is an ideal additional marker for
determining clinical activity in UC and should be investigated in a
larger patient cohort.
Under baseline conditions, the NE is controlled by intracellular
compartmentalisation within granules of neutrophils, and if
released, its activity is antagonised by extracellular inhibitors.
The continual and excessive release of NE at inflammatory sites or
disruption to inhibitor function can push the balance in favour of
NE activity, which causes tissue injury. Elevated levels of NE are
detected in colonic mucosal tissue and plasma samples from UC
patients and therefore measurement of NE abundance has
previously been explored as a biomarker for IBD.35–37 However,
NE abundance does reliably indicate active disease in IBD,38 and is
inferior to other faecal markers, for example, calprotectin and
lactoferrin.35 This is likely due to the concatenate release of
endogenous NE inhibitors. Corroborating this notion, the human
orthologues of SerpinA3N, α-1-antitrypsin (SERPINA1) and α-1-
antichymotrypsin (SERPINA3) are increased in serum and faeces
from IBD patients.39–41 These previous studies have focused on
total protein levels and not the actual activity of NE. In this study,
using the C. rodentium infection model, we demonstrate that
SerpinA3N is produced and released by infected IECs to mitigate
NE activity. To our knowledge, this is the first time a host Serpin
has been implicated in infectious colitis. In mice with mild disease
symptoms, no faecal NE activity is detected due to sufficient
expression of SerpinA3N. In contrast, in mice suffering from severe
symptoms, faecal NE activity results from an imbalance with
SerpinA3N, likely due to the prolonged neutrophil recruitment
and/or excessive release of NE (Fig. 8).
Due to the damaging effects of uncontrolled NE activity, NE has
been explored as a potential therapeutic target using the DSS
colitis model. Previous studies have demonstrated that treatment
with Sivelestat or administration of SERPINA1 and Elafin (human
NE inhibitors) attenuates disease.42–44 In contrast to these studies,
we have used a natural murine NE inhibitor, SerpinA3N, to target
NE in a physiological model of infection-induced colitis. By using
the pathogen to specifically deliver SerpinA3N to the site of
infection, we observed reduced NE activity and tissue damage.
This suggests that delivering Serpins specifically to the inflamed
site, that is, using engineered commensal Gram-negative bacteria,
may be useful for treating inflammatory diarrheal diseases. In
addition, there is an urgent need for alternative therapies for IBD
patients, which do not respond to current first-line treatments.45
To help meet this clinical gap, we propose the possibility of
screening specifically for patients for NE activity and treating this
subset with NE inhibitors.
In summary, our results demonstrate that uncontrolled neu-
trophil responses contribute to the detriment of the host. During
colitis induced by pathogen or as a result of chronic disease
extracellular NE is regulated by antiproteases such as SerpinA3N.
However, an imbalance resulting in excessive NE activity causes
tissue damage, which likely heightens colitis pathology (Fig. 8).
Thus, our results reveal that it is NE activity not NE abundance that
should be the focus of prognostic tests for IBD management.
Furthermore, modifying the NE-antiprotease balance by employing
bacteria to deliver auxiliary Serpins specifically at the inflammatory
site offers a novel approach for treating enteric infections and IBD.
MATERIALS AND METHODS
Patient sample collection
Faecal samples were collected from patients with confirmed IBD,
diagnosed by experienced gastroenterologists. Samples collected
within 6 h of production were divided and stored at −80 °C or sent
for calprotectin analysis. Clinical data, including disease type and
location, were recorded and each patient’s DAI calculated (Table 1).
The DAI was determined using the simple clinical colitis activity
index (SCCAI). Ethical approval for the research was given by
Stanmore REC (IRAS 243310).
In vivo infection
Animal experiments complied with the Animals Scientific Proce-
dures Act 1986 and UK Home Office guidelines and were
approved by the local ethical review committee. Experiments
were designed in agreement with the ARRIVE guidelines46 for the
reporting and execution of animal experiments, including sample
randomisation and blinding. Mouse experiments were performed
with 3–5 mice/group and repeated at least two times indepen-
dently. Pathogen-free female 18–20 g C57 and 20–25 g C3H mice
(Charles River Laboratories, Italy) were housed in high-efficiency
particulate air-filtered cages with sterile bedding and given ad
libitum access to food and water. Mice were infected with C.
rodentium by oral gavage and bacterial colonisation monitored.
DSS treatment
DSS was added to sterilised water at a concentration of 1.5% or
3% (wt/vol) and administered to C57 mice for 6 days ad libitum. At
day 6, DSS was replaced with sterilised water and mice were
harvested 2 days later. Mice were weighed and faecal samples
collected over the duration of the experiment and DIA recorded
(Table S3).
Faecal sample collection and protein extraction
Faecal samples were collected in LoBind tubes (Eppendorf), placed
on ice and resuspended at 1 g/10ml in cold faecal protein
extraction buffer (FPEB; 50mM Tris, pH 7.5, 150mM NaCl).
Samples were homogenised and incubated on ice for 30 min
with a brief vortex every 5 min. Samples were centrifuged at
2000 × g at 4 °C for 10min. The supernatant (S/N) was collected
and filtered using a 0.2 μM column (Costar) by centrifugation at
15,800 × g at 4 °C for 30 min. The flow through was transferred to a
LoBind tube and stored at −80 °C. Human faecal samples were
defrosted on ice and processed as described.
NE activity assay
NE activity was measured in faecal samples or recombinant (r)
protein pre-mixes through the fluorescence released after NE-
induced cleavage of MeOSuc-Ala-Ala-Pro-Val-AMC (Bachem) at a
Fig. 7 Delivery of SerpinA3N at the site of infection reduces faecal NE activity and disease severity in C3H mice. a Western blot analysis of
SerpinA3N-HylA in a culture supernatant obtained from ICC2031. b Rate of cleavage of NE substrate by 10 nM recombinant neutrophil elastase
(rNE) following incubation with BSA (control), affinity-purified SerpinA3N-HlyA and rSerpinA3N. c Shedding of WT C. rodentium (circles) and
ICC2031 (inverted triangles) upon infection of C3H mice. Number of CFU/g of stool was measured 6 dpi. d The number of Ly6G-positive cells
were counted per colonic section from individual mice (n= 8–9). e S100A8 ELISA (calprotectin) shows no significant difference between mice
infected with WT C. rodentium (circles) and ICC2031 (inverted triangles) at 6 dpi. Multiple comparison one-way ANOVA was performed; *P ≤
0.05, ***P ≤ 0.001. f MPO ELISA shows no significant difference between mice infected with WT C. rodentium (circles) and ICC2031 (inverted
triangles) at 6 dpi. Multiple comparison one-way ANOVA was performed; **P ≤ 0.01, ***P ≤ 0.001. g Analysis of faecal NE activity in samples
collected pre-infection (uninfected) and 6 dpi. Cyan inverted triangles indicates outliers determined by ROUT test, Q= 0.5%. Multiple
comparison one-way ANOVA was performed, ***P ≤ 0.001. h Quantification of the number of TUNEL-positive cells per transverse section
of colons from individual mice. Cyan inverted triangles correspond to outliers based on NE activity. Mann–Whitney test, **P ≤ 0.01. i Survival
curve of C3H mice infected with WT C. rodentium (n= 14) and ICC2031 (n= 15); combined data from three biological repeats. Comparison of
survival curves by log-rank (Mantel–Cox) test; *P= 0.0302. j Diarrhoeal score of mice infected with WT C. rodentium (n= 14; black line) and
ICC2031 (n= 15; grey line) over time; combined data from three biological repeats. Multiple t tests, *P ≤ 0.05 (11 dpi).
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final concentration of 100 μM or MeOSuc-Arg(NO2)-Met(O2)-Oic-
Abu-ACC at a final concentration of 10 μM. For MeOSuc-Ala-Ala-
Pro-Val-AMC, 25 μl of mouse faecal sample was used. For MeOSuc-
Arg(NO2)-Met(O2)-Oic-Abu-ACC, mouse or human faecal samples
were diluted 1:5 or 1:25 in FPEB (±10 μM Sivelestat), respectively.
Samples were mixed 1:1 with the NE substrate diluted in NE assay
buffer to a final volume of 50 μl. Fluorescence was measured using
FLUOstar Omega microplate reader (BMG Labtech) at excitation/
emission wavelengths of 355 nm/460 nm up to 2 h, with a 30 s
interval time. A linear regression fit on the linear portion of each
progress curve was performed to calculate the slope of line (rate
of substrate cleavage). A multiple comparison one-way ANOVA
(analysis of variance) was performed comparing the slope of the
regression lines (Prism 7).
Mouse rNE was activated by incubating with cathespin C for 2 h
at 37 °C in 50mM MES (2-(N-morpholino)ethanesulfonic acid), pH
5.5, and diluted to 1–5 nM in NE assay buffer in a 20 μl volume and
mixed with rSerpinA3N (3.125–100 nM), faecal sample, purified
culture supernatant (SerpinA3N-HylA), Sivelestat or bovine serum
albumin (BSA) diluted in FPEB to 20 μl volume. Pre-mixes were
incubated in a black-walled 96-well plate for 30min at 37 °C prior
to the addition of the optimised NE substrate diluted in NE assay
buffer to 10 μl. Readings were measured immediately, and analysis
performed as described above.
Western analysis
Enterocytes were lysed in Triton lysis buffer+ 1% sodium dodecyl
sulfate (SDS), passed through 0.8ml columns (Pierce) to shred
genomic DNA and protein concentration was estimated using the
BCA Protein Assay Kit (Pierce). Faecal extracts were lysed directly in
6× SDS loading dye. Proteins were separated by SDS-polyacrylamide
gel electrophoresis using 4–20% TGX gels (Bio-Rad) and transferred
to PVDF membranes using the Bio-Rad Trans-Blot® semi-dry transfer
cell. Membranes were blocked for 1 h with 5% skim milk/TBST
before sequential incubation with primary antibodies in 5% BSA/
TBST and secondary antibodies in 5% skim milk/TBST for 1 h each
with washing in between. Blots were visualised using Clarity ECL
(Bio-Rad) and the ChemiDocTM imaging system (Bio-Rad). Bands
were quantified using the Image Lab software (Bio-Rad).
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Fig. 8 Model demonstrating the interplay between NE and SerpinA3N during infection. a Citrobacter rodentium infection induces the
recruitment of neutrophils. In response to inflammatory triggers NE is released. SerpinA3N is produced and secreted by infected IECs to protect
from NE-induced damage. In mild disease (e.g. C57 mice), the balance is in favour of the inhibitor (i.e. excess free SerpinA3N). b In severe disease
(e.g. C3H mice), there is insufficient SerpinA3N to neutralise excess luminal NE activity, which results in IEC cell death (grey cell with fragmented
membrane and nuclei). c The balance can be pushed in favour of the inhibitor in C3H mice using engineered C. rodentium to deliver SerpinA3N.
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